Download
https://www.ndtvprofit.com/business/strides-pharmas-tentative-approved-hiv-drug-to-generate-revenues-only-after-2027?utm_source=telegram&utm_medium=referral&utm_campaign=socialshare
The patent expiry is in May 2027 and there are seven other players with tentative approvals for the HIV drug.
Share